Morgan Stanley analyst Sean Laaman maintained a Buy rating on BeiGene (BGNE – Research Report) on December 3 and set a price target of $300.00. The company’s shares opened today at $204.47.
Citing the company's growth possibilities linked to its main medicine, Brukinsa (zanubrutinib), Morgan Stanley assigned BeiGene (BGNE, Financials) with an overweight rating. The investment bank ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback